Forde Colin P, Mortimer Crispin, Smith Toby O, Costa Matthew L, Cook Jonathan A, Tutton Elizabeth, Wistow Georgina, Minty Paul, Keene David J
Oxford Trauma and Emergency Care, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Physiotherapy Department, Tavistock Hospital, University Hospitals Plymouth, Plymouth, UK.
Bone Jt Open. 2025 Sep 4;6(9):1031-1043. doi: 10.1302/2633-1462.69.BJO-2025-0045.R1.
The primary aims were to determine what outcome domains, outcome measurement instruments, and outcome measurement timepoints are reported in randomized controlled trials (RCTs) involving people with patellar dislocations. The secondary aims were to determine what primary outcomes were used and how a recurrent patellar dislocation was defined when this was used as an outcome.
We searched MEDLINE, Embase, CINAHL, the Cochrane Database of Controlled Trials, and trial registries (last search: January 2024) for RCTs evaluating treatments for people with a patellar dislocation irrespective of age or sex. We identified the unique outcomes in included studies and mapped these onto the World Health Organization's International Classification of Functioning, Disability and Health (WHO ICF) framework to identify the measured domains. We synthesized results into tables, figures, and text. A critical appraisal of included studies was not required for this systematic review.
From the 70 included studies, we identified 141 unique outcomes. The most commonly used unique outcome was a recurrent ipsilateral patellar dislocation (used in 55 studies), but only 17/55 studies (31%) reported how this was defined (i.e. the criteria required for a recurrent ipsilateral patellar dislocation event to be recorded). Unique outcomes mapped onto 66 second-level domains of the WHO ICF framework, and 56% (593/1,052) in the 'activities and participation' domain. Included studies used 42 different patient-reported outcome measures (PROMs), most commonly the Kujala Patellofemoral Score (71%, 50/70 studies), but 28 PROMs (60%) were used only once. In all, 31 different primary outcomes were identified from 47 included studies, with 14 primary outcomes (45%) used only once among included studies. The Kujala Patellofemoral Score was also the most common primary outcome (38%, 18/47 studies). Outcome measurement timepoints varied, but the most common timeframe for primary outcome measurement was > one to three years (46%, 16/35 studies that provided data).
The variability in the outcome domains, PROMs, and primary outcomes measured in RCTs evaluating patellar dislocation treatments highlights that a core outcome set is needed. This process is underway and is being informed by this systematic review's findings.
主要目的是确定在涉及髌骨脱位患者的随机对照试验(RCT)中报告了哪些结局领域、结局测量工具和结局测量时间点。次要目的是确定使用了哪些主要结局,以及当将复发性髌骨脱位用作结局时是如何定义的。
我们检索了MEDLINE、Embase、CINAHL、Cochrane对照试验数据库和试验注册库(最后一次检索时间:2024年1月),以查找评估髌骨脱位患者治疗方法的RCT,无论年龄或性别。我们确定了纳入研究中的独特结局,并将这些结局映射到世界卫生组织的《国际功能、残疾和健康分类》(WHO ICF)框架中,以确定所测量的领域。我们将结果综合成表格、图表和文本。本系统评价不需要对纳入研究进行严格评价。
从70项纳入研究中,我们确定了141个独特结局。最常用的独特结局是同侧复发性髌骨脱位(55项研究中使用),但只有17/55项研究(31%)报告了其定义方式(即记录同侧复发性髌骨脱位事件所需的标准)。独特结局映射到WHO ICF框架的66个二级领域,其中56%(593/1052)在“活动与参与”领域。纳入研究使用了42种不同的患者报告结局测量工具(PROMs),最常用的是库贾拉髌股关节评分(71%,50/70项研究),但28种PROMs(60%)仅使用过一次。总共从47项纳入研究中确定了31种不同的主要结局,其中14种主要结局(45%)在纳入研究中仅使用过一次。库贾拉髌股关节评分也是最常见的主要结局(38%,18/47项研究)。结局测量时间点各不相同,但主要结局测量最常见的时间范围是>1至3年(46%,16/35项提供数据的研究)。
评估髌骨脱位治疗方法的RCT中所测量的结局领域、PROMs和主要结局的变异性突出表明需要一个核心结局集。这一过程正在进行中,并将参考本系统评价的结果。